Abstract:2022-RA-886-ESGO Figure 1 Conclusion 8.1% of endometrial cancer patients undergoing minimally invasive surgery with intrauterine manipulation showed positive peritoneal cytology conversion associated with significantly worse oncological outcome. 2022-RA-888-ESGO ROLE OF PREOPERATIVE DETERMINATION OF MOLECULAR CLASSIFICATION ON ENDOMETRIAL BIOPSY IN PREOPERATIVE ALLOCATION INTO A RISK CATEGORY IN ENDOMETRIAL CANCER Laura Cárdenas Puiggrós, Pedro Alberto Corzo Orantos, Anna Taltavull Pons, Isabel Núñez Márquez, Rocio Garcia BerrioCristina Meléndez Muñoz, Pilar Barretina Ginesta, Hugo Javier Rosales González, Eduard Sala Hernández, Elena Álvarez Castaño. Gynaecological Oncology Unit, Dr. Josep Trueta University Hospital, Girona, Spain; Pathology Department, Dr. Josep Trueta University Hospital, Girona, Spain; Medical Oncology, Catalan Institute of Oncology, Girona, Spain; Radiation Oncology, Catalan Institute of Oncology, Girona, Spain 10.1136/ijgc-2022-ESGO.254 Introduction/Background Traditional risk classification in endometrial cancer was based on clinicopathological data. Preoperative assessment is used to tailor the extend of surgery. The TCGA surrogate has been recently incorporated into risk stratification by ESGO-ESTRO-ESP guidelines. The aim of this study is to evaluate if preoperative determination of molecular classification is feasible and can improve preoperative estimation of risk group. Methodology In this retrospective cohort study, we identified all newly clinical early-stage endometrial cancer cases operated between January 2021 and April 2022. All cases had preoperative MRI and endometrial biopsy where molecular classification was done. Patients were allocated to a risk group based on 2021 ESGO-ESTRO-ESP guidelines by three Methods using only preoperative clinicopathological data, using preoperative molecular and clinicopathological data, using postoperative molecular and clinicopathological data. Results 55 cases were included. In all cases molecular classification was done preoperative while the patient was in waiting list. In figure 1, concordance between preoperative and postoperative assessment is shown. Abstract 2022-RA-888-ESGO Figure 1 Relation between preoperative and postoperative risk assessment2022-RA-888-ESGO Figure 1 Relation between preoperative and postoperative risk assessment When molecular classification is only taken account postoperatively, the Cohen’s kappa coefficient for the concordance is 0.37 (95% CI= 0.20–0.54) and risk was underestimated in 16/55 (29.1%) and overestimated in 8/55 (14.5%). If molecular classification is added to preoperative assessment, the Cohen’s kappa coefficient is 0.54 (95% CI= 0.38–0.70) and risk was underestimated in 12/55 (21.9%) and overestimated in 5/55 (10.0%). Overall agreement between preoperative and postoperative assessment for hystotype was 89.1%, for grade was 74.5%, and between radiologic and definitive stage was 74.5%. Conclusion Preoperative determination of molecular classification is feasible and seems to increase the reliability of preoperative risk stratification. However, in around 22% of cases risk is still underestimated leading to inadequate surgery strategy. Sentinel lymph node biopsy can elegantly overcome this problem by providing information on the lymph node status with minimal morbidity and its implementation should be

Correspondence on 'Predicting the risk of nodal disease with histological and molecular features in endometrial cancer: the prospective PROME trial by Bogani et al

Response to: Correspondence on 'Predicting the risk of nodal disease with histological and molecular features in endometrial cancer: the prospective PROME trial by Aznar et al

Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis

Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort

Biomolecular Classification in Endometrial Cancer: Onset, Evolution, and Further Perspectives: A Critical Review

Molecular classification improves preoperative risk assessment of endometrial cancer

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer

Correspondence on 'Long-term survival outcomes in high-risk endometrial cancer patients undergoing sentinel lymph node biopsy alone versus lymphadenectomy' by Capozzi et al

Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer

Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early‐stage endometrial cancer: A propensity score–matched analysis

Correspondence on "Sentinel lymph node assessment in patients with atypical endometrial hyperplasia: a systematic review and meta-analysis" by Vieira-Serna et al

Molecular classification of endometrial cancer: preliminary experience from a single Portuguese academic center

Practical lessons learned from real-world implementation of the molecular classification for endometrial carcinoma

2022-RA-888-ESGO Role of preoperative determination of molecular classification on endometrial biopsy in preoperative allocation into a risk category in endometrial cancer

Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer

Update in the molecular classification of endometrial carcinoma

Impact of molecular classification on recurrence risk in endometrial cancer patients with lymph node metastasis: multicenter retrospective study

Low-Risk and High-Risk NSMPs: A Prognostic Subclassification of No Specific Molecular Profile Subtype of Endometrial Carcinomas

Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series

Prognostic molecular biomarkers in endometrial cancer: A review

Molecular classification of endometrial carcinoma on endometrial biopsy: an early prognostic value to guide personalized treatment